Rezultati pretraživanja
  1. 17. ruj 2018.

    Patients don’t want to come to the “heart failure”clinic. Let’s focus our efforts on reverse remodeling and .

  2. 5. kol 2017.

    VIDEO: What should uro-oncologists know about in 2017? ,

  3. In 2017, 33% of coming to market were . Read more about 2017 FDA approvals in our article

  4. URL: https://bit[.]ly/2HDMErt FDA gave the green light to 59 novel orphan drugs, the most it has approved in nearly two decades.

  5. 17. kol 2019.

    The early bird registration deadline has been extended..!! Grab the opportunity........!! Register under the early bird to get a discount 😀😀

  6. 22. pro 2016.

    looks for for diseases with high unmet medical need Deadline Dec 31, 2016

  7. 28. pro 2015.

    In silico drugs has unveiled a new way discovering novel drugs.

  8. Prikaži ovu nit
  9. 9. kol 2019.

    Hurry Up......!! Get a discount of $100 on your registration fee by registering under early-bird registration. For Registration visit:

  10. 29. svi 2018.

    can help in finding for by identifying & can provide information about possible and , indicate interesting and suggest .

  11. Submit the abstarct to the track and present your findings in at, ,UAE during December 5-6, 2018 👇👇comment below. Martina Johnson| Program Coordinator Email id: pharmaceutics@annualmeetings.net

  12. 24. kol 2018.
  13. 5. lip 2014.
  14. Compugen Discloses Predictive Structural Biology Infrastructure Platform for Enhanced Discovery of

  15. URL: There were 35 and biologics approved in 2018 with . This is the highest number since the passage of the Act in 1983. for more

  16. 7. sij 2019.

    34 of 59 novel drugs (58%) approvals by the FDA in 2018 were approved to treat rare or “orphan” diseases (from the FDA’s Center for Drug Evaluation and Research’s CDER annual report)

  17. 28. ožu 2018.

    are caused by microorganisms such as , , and Its market expected to expand at 6.6% CAGR over the forecast period (2014-2025) driven by the need for to fight . Read More @

  18. 14. stu 2019.

    Promising new combination therapy for HDV hepatitis. ▶️Lonafarnib is a prenylation inhibitor.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.